Research Papers:

An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites

Xinping Fu, Armando Rivera, Lihua Tao and Xiaoliu Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:902-914. https://doi.org/10.18632/oncotarget.2817

Metrics: PDF 2325 views  |   HTML 3097 views  |   ?  


Xinping Fu1,*, Armando Rivera1,*, Lihua Tao1 and Xiaoliu Zhang2

1 Department of Biology and Biochemistry and Center for Nuclear Receptors and Cell Signaling, University of Houston, Texas, USA

2 Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA

* These authors contributed equally to this work


Xiaoliu Zhang, email:

Keywords: oncolytic virus, adoptive T cell transfer, chemokines, T cell migration, antitumor immunity

Received: October 10, 2014 Accepted: November 24, 2014 Published: November 25, 2014


Adoptive T-cell therapy has shown promises for cancer treatment. However, for treating solid tumors, there is a need for improving the ability of the adoptively transferred T cells to home to tumor sites. We explored the possibility of using an oncolytic virus derived from HSV-2, which can actively pull T effector cells to the site of infection, as a local attractant for migration of adoptively transferred T cells. Our data show that intratumoral administration of this virus can indeed attract active migration of the adoptively transferred T cells to the treated tumor. Moreover, once attracted to the tumor site by the virus, T cells persisted in there significantly longer than in mock-treated tumor. Chemokine profiling identified significant elevation of CXCL9 and CXCL10, as well as several other chemokines belonging to the inflammatory chemokine family in the virus-treated tumors. These chemokines initially guided the T-cell migration to and then maintained their persistence in the tumor site, leading to a significantly enhanced therapeutic effect. Our data suggests that this virotherapy may be combined with adoptive T-cell therapy to potentiate its therapeutic effect against solid tumors that are otherwise difficult to manage with the treatment alone.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2817